Season 2, Episode 13

This week’s episode, we will learn more about the feasibility of combining IDH inhibitors with intensive chemotherapy in patients with newly diagnosed IDH-mutant AML, review a phenotypic and functional analysis of the inflammatory infiltrate in the Langerhans Cell Histiocytosis lesion, and discuss the results of a Phase 3 trial in patients with hemophilia A evaluating prophylactic factor replacement therapy targeting two different Factor VIII trough levels for prevention of bleeds.

Released April 1, 2021

The articles highlighted in this episode are listed below:

• Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

  Authors: Eytan M. Stein , Courtney D. DiNardo , Amir T. Fathi , Alice S. Mims , Keith W. Pratz , Michael R. Savona , Anthony S. Stein , Richard M. Stone , Eric S. Winer , Christopher S. Seet , Hartmut Döhner , Daniel A. Pollyea , James K. McCloskey , Olatoyosi Odenike , Bob Löwenberg , Gert J. Ossenkoppele , Prapti A. Patel , Mikhail Roshal , Mark G. Frattini , Frederik Lersch , Aleksandra Franovic , Salah Nabhan , Bin Fan , Sung Choe , Hongfang Wang , Bin Wu , Lei Hua , Caroline Almon , Michael Cooper , Hagop M. Kantarjian , Martin S. Tallman

• Taking aim at IDH in fitter patients with AML

  Authors: Andrew H. Wei , Naval Daver

• Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH

  Authors: Amel Sengal , Jessica Velazquez , Meryl Hahne , Thomas M. Burke , Harshal Abhyankar , Robert Reyes , Walter Olea , Brooks Scull , Olive S. Eckstein , Camille Bigenwald , Catherine M. Bollard , Wendong Yu , Miriam Merad , Kenneth L. McClain , Carl E. Allen , Rikhia Chakraborty

• Double trouble for Langerhans cell histiocytosis

  Authors: Michelle L. Hermiston

• Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

  Authors: Robert Klamroth , Jerzy Windyga , Vlad Radulescu , Peter W. Collins , Oleksandra Stasyshyn , Hishamshah Mohd Ibrahim , Werner Engl , Srilatha D. Tangada , William Savage , Bruce Ewenstein

• Prophylaxis in hemophilia: how much is enough?

  Authors: Christine L. Kempton